Oragenics,
Inc. (OTCBB: OGEN) (the “Company”) announced today that its common
stock has been approved for listing on the NYSE Euronext's NYSE
MKT. Trading is expected to commence on the NYSE MKT on Wednesday,
April 10, 2013 under the ticker symbol ‘OGEN’.
“We are pleased to begin trading on NYSE MKT,” said John N. Bonfiglio
PhD, President and CEO of Oragenics. “This listing marks an important
step in our Company’s development by giving us greater access to a
broader investor base and by providing increased transparency and
liquidity for the financial community.”
“We welcome Oragenics, Inc. to the NYSE MKT family of listed companies,”
Scott Cutler, Executive Vice President, Global Listings at NYSE
Euronext. “Oragenics will be joining other growth oriented companies in
the U.S. taking advantage of the NYSE’s advanced and innovative market
model to offer a premier value for listing and trading their stocks.”
The listing approval is contingent on the Company continuing to meet all
of the initial listing requirements on the day it is scheduled to
commence trading.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics, Inc. has established an exclusive
worldwide channel collaboration for lantibiotics, a novel class of broad
spectrum antibiotics, with Intrexon Corporation Inc., a synthetic
biology company. The collaboration will allow Oragenics access to
Intrexon's proprietary technologies with the idea of accelerating the
development of much needed new antibiotics that will work against
resistant strains of bacteria. Oragenics also develops, markets and
sells proprietary probiotics specifically designed to enhance oral
health for humans and pets, under the brand names Evora
and ProBiora
in over 13 countries worldwide.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond June 30, 2012
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
